FENNEC PHARMACEUTICALS INC (FRX)

Equity

Sell: 10.49 CAD|Buy: 11.70 CAD|Change: 0.06 (-0.54%)

Open

10.13 CAD

Previous close

10.26 CAD

Trade high

10.205 CAD

Volume

Year high

13.83 CAD

Year low

7.02 CAD

Dividend yield

–

Market capitalisation

348.54 mn CAD

P/E ratio

74.38

ISIN

CA31447P1009

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 02/02/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
FENNEC PHARMACEUTICALS INC	0.00
More...

Company profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.